Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

• Status: Enrolling by invitation
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corcept Therapeutics

Criteria

Inclusion Criteria:

• Major Inclusion Criteria:

• Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome with at least 80% compliance with the dosing schedule.

• According to the Investigator's opinion will benefit from continuing treatment with relacorilant

Exclusion Criteria:

• Major Exclusion Criteria:

• Premature discontinuation from a relacorilant parent study.

• Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism

• Has poorly controlled hypertension

• Has Stage ≥ 4 renal failure